|
Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes
|
May 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes
|
May 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients With Myelodysplastic Syndromes: Results of a Large Web-Based Survey
|
Jun 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Raising the bar for lower-risk myelodysplastic syndromes
|
Jun 2023
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
|
Oct 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Eat and be healthy: nutritional status in myelodysplastic syndromes
|
Jul 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy
|
Oct 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions
|
Jul 2020
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis
|
Jun 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents
|
Dec 2020
|
Leukemia Research
|
myelodysplastic syndromes (MDS)
|
